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Abstract 
Introduction 
Non-small cell lung cancer (NSCLC) arises when epithelial cells lining the 
bronchial tubes undergo aberrant cell growth due to up-regulation of pro-
grammed death (PD-1) ligands, thereby affording evasion of immune surveil-
lance. Pembrolizumab, a monoclonal antibody, is an immune checkpoint in-
hibitor. By blocking PD-1 from binding its ligands, programmed death ligand 
(PD-L1) and programmed death 2 (PD-L2), pembrolizumab restores T-cell ac-
tivation, enabling effective detection and destruction of tumour cells. 
Methodology 
Published and grey literature were identified by searching the Cochrane Li-
brary, CRD Database, Embase, Ovid Medline, PubMed, Internet sites and con-
tacting the manufacturer. Quality assessment was conducted to assess the risk 
of bias at the study level and the applicability of study results. Furthermore, 
the magnitude of clinically meaningful benefit that can be expected from pem-
brolizumab was evaluated based on, both the original and adapted version of, 
the Magnitude of Clinical Benefit Scale developed by the European Society for 
Medical Oncology. 
Results of the KEYNOTE-042 trial 
KEYNOTE-042, an ongoing, randomised, open-label, phase III trial compared 
the efficacy and safety of pembrolizumab (200 mg IV; every 3 weeks up to 35 
cycles) versus platinum-based chemotherapy (carboplatin + paclitaxel or 
pemetrexed; up to six cycles) as first-line therapy for 1.274 patients with PD-
L1-expressing metastatic NSCLC. Pembrolizumab increased overall survival 
(OS) by 7.8 months, 4.7 months, and 4.6 months for patients with PD-L1 tu-
mour proportion scores (TPS) ≥50%, ≥20%, and ≥1%, respectively. The OS 
benefit of pembrolizumab over chemotherapy was demonstrated across three 
PD-L1 TPS populations; PD-L1 TPS ≥50% derived the greatest benefit. An ex-
ploratory analysis found no OS benefit for those with PD-L1 TPS 1–49% (n = 
675, 13.4 months versus 12.1 months; HR 0.92, 95% CI 0.77–1.11, no statisti-
cally significant difference). No statistically significant differences in progres-
sion-free survival (PFS) or overall response rate (ORR) were noted between 
groups in any PD-L1 TPS population. Pneumonitis (8%) was the most fre-
quently reported adverse event of grade ≥3 in severity. Common immune-
mediated AEs occurring in pembrolizumab patients included hypothyroidism 
(12%), hyperthyroidism (6%), skin reactions (2%), colitis (1%) and hepatitis 
(1%).  
Conclusion 
Overall, first-line pembrolizumab monotherapy increases OS for patients with 
PD-L1-expressing metastatic NSCLC. Comprising 46.6% of the ITT population, 
the greatest OS benefit of pembrolizumab over chemotherapy was observed 
in patients with PD-L1 TPS ≥50%. No statistically significant difference in OS 
was noted between groups for those with PD-L1 TPS 1–49%; and no 
statistically significant differences in PFS or ORR were noted in any PD-L1 TPS 
population. Data regarding QoL and CNS activity are needed to ensure 
patients derive a clinically relevant benefit over time despite manageable 
toxicity. Further biomarkers are needed to ensure the appropriate patient 
selection and facilitate comparison with other immune checkpoint inhibitors 
In the absence of direct comparison trials, physicians may need to discuss 
whether adding pembrolizumab to chemotherapy would provide greater 
individual efficacy than chemotherapy alone, especially for PD-L1 TPS 1–49% 
patients.  
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1 Research questions 
The HTA Core Model® for Rapid Relative Effectiveness Assessment of Phar-
maceuticals was used for structuring this report [1]. The Model organises HTA 
information according to pre-defined generic research questions. Based on 
these generic questions, the following research questions were answered in 
the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is pembrolizumab? 
A0022 Who manufactures pembrolizumab? 
A0007 What is the target population in this assessment? 
A0020 For which indications has pembrolizumab received marketing authorisation? 
Health problem and current use 
A0002 What is NSCLC in the scope of this assessment? 
A0004 What is the natural course of NSCLC? 
A0006 What are the consequences of NSCLC for society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of NSCLC? 
A0003 What are the known risk factors for NSCLC? 
A0024 How is NSCLC currently diagnosed according to published guidelines and in practice? 
A0025 How is NSCLC currently managed according to published guidelines and in practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of pembrolizumab on mortality? 
D0005 How does pembrolizumab affect symptoms and findings (severity, frequency) of NSCLC? 
D0006 How does pembrolizumab affect progression (or recurrence) of NSCLC? 
D0011 What is the effect of pembrolizumab on patients ̕ body functions? 
D0012 What is the effect of pembrolizumab on generic health-related quality of life? 
D0013 What is the effect of pembrolizumab on disease-specific quality of life? 
Safety 
C0008 How safe is pembrolizumab in relation to the comparator(s)? 
C0002 Are there harms related to dosage or frequency of applying pembrolizumab? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of pembrolizumab? 
A0021 What is the reimbursement status of pembrolizumab? 
 
 
 
 
EUnetHTA 
HTA Core Model® 
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2 Drug description 
Generic/Brand name/ATC code:  
Pembrolizumab/Keytruda®/MK-3475/L01XC18 
 
B0001: What is the technology and the comparator(s)? 
Up-regulation of programmed death 1 (PD-1) ligand in patients with tumours 
increases the propensity for cancer cells to evade immune surveillance. Pem-
brolizumab, a monoclonal antibody, is an immune checkpoint inhibitor. By 
blocking PD-1 from binding its ligands, programmed death ligand 1 (PD-L1) 
and programmed death ligand 2 (PD-L2), pembrolizumab restores T-cell ac-
tivation, enabling effective detection and destruction of tumour cells [2].  
Pembrolizumab is available as single-use vials of 50 mg powder for reconsti-
tution (25 mg/mL) or 100 mg/4 mL infusion solution. It is administered as an 
intravenous (IV) infusion over 30 minutes, at a dose of 200 mg every three 
weeks for up to 35 treatments, until disease progression or unacceptable tox-
icity. For melanoma and previously treated NSCLC, the dose depends on the 
patient’s weight and is 2 mg/kg body weight [3].  
Patients should be monitored for symptoms of immune-mediated pneumon-
itis, colitis, hepatitis, endocrinopathies, and nephritis. Dose interruption or 
discontinuation may be necessary in patients that develop pneumonitis, coli-
tis, hypophysitis, thyroid disorders, type 1 diabetes mellitus, nephritis, hepa-
titis, infusion-related reactions, or intolerance due to adverse events (AEs) 
[4]. While systemic corticosteroids or immunosuppressants should be 
avoided prior to starting pembrolizumab, due to the potential for pharmaco-
dynamics interference, they may be used to treat immune-related AEs after 
starting pembrolizumab [5]. 
 
 
A0022: Who manufactures the technology? 
Merck Sharp & Dohme Corporation, a subsidiary of Merck & Company Incor-
porated 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Pembrolizumab (Keytruda®) is indicated as first-line monotherapy for pa-
tients with PD-L1 expressing (tumour proportion score [TPS] 1), locally 
advanced or metastatic non-small cell lung cancer (NSCLC) without epider-
mal growth factor receptor (EGFR) mutations or anaplastic lymphoma ki-
nase (ALK) rearrangements [6]. 
PD-1, immune 
checkpoint inhibitor 
pembrolizumab (200 
mg IV) every 3 weeks 
for up to 35 cycles 
monitor for immune-
mediated AEs; withhold 
or discontinue for 
safety/tolerability  
previously untreated, 
PD-L1-expressing 
metastatic NSCLC  
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4 Current regulatory status 
A0020: For which indications has the technology received marketing authori-
sation? 
Pembrolizumab was granted its first global approval by the US Food and Drug 
Administration (FDA) in September 2014 for the treatment of refractory un-
resectable or metastatic melanoma [7]. In October 2015, pembrolizumab was 
approved for the treatment of patients with metastatic NSCLC whose tumours 
express PD-L1 as determined by an FDA-approved test, with progression fol-
lowing platinum-based chemotherapy or targeted therapy for EGFR or ALK 
aberrations. The companion diagnostic, PD-L1 immunohistochemistry (IHC) 
22C3 pharmDx assay (Agilent Technologies, CA, USA), was approved concur-
rently and CE marked for European use. Approval was based on the overall 
response rate (ORR) in a subset of phase Ib KEYNOTE-001 patients where at 
least 50% of tumour cells expressed PD-L1 (TPS ≥50%) and overall survival 
(OS) data from the phase III KEYNOTE-010 study [2, 7-9]. 
In October 2016, the FDA approved pembrolizumab as first-line therapy for 
metastatic NSCLC demonstrating high PD-L1 expression (TPS ≥50%) without 
EGFR or ALK aberrations. Approval was based on progression-free survival 
(PFS) and OS data from the phase III KEYNOTE-024 study [10, 11]. Combina-
tion pembrolizumab with pemetrexed and carboplatin received accelerated 
approval as first-line treatment for metastatic non-squamous NSCLC, irre-
spective of PD-L1 expression, following results of the KEYNOTE-021 study in 
May 2017 [12]. From August to October 2018, combination pembrolizumab 
with chemotherapy was approved as first-line treatment for metastatic non-
squamous and squamous NSCLC, based on OS and PFS data from the phase III 
KEYNOTE-189 and KEYNOTE-407 trials, respectively [13, 14]. In April 2019, 
first-line pembrolizumab monotherapy indications were expanded to include 
stage III or IV NSCLC patients who are not candidates for surgery or chemora-
diation, and whose tumours express PD-L1 (TPS 1). Expanded approval was 
based on OS data from the phase III KEYNOTE-042 study [6]. 
Pembrolizumab received marketing authorisation by the European Medicines 
Agency (EMA) in July 2015, and is approved for the treatment of metastatic 
melanoma, advanced NSCLC, classical Hodgkin lymphoma, urothelial cancer, 
advanced renal cell carcinoma, and head and neck squamous cell carcinoma 
[3]. It is licensed as first-line monotherapy for metastatic NSCLC exhibiting 
high PD-L1 expression without EGFR or ALK aberrations, and as second-line 
therapy following progression on platinum-based chemotherapy. Pembroli-
zumab in combination with chemotherapy is licensed as first-line treatment 
of metastatic non-squamous and squamous NSCLC. An application to extend 
the first-line indication of pembrolizumab in NSCLC with PD-L1 (TPS 1) is 
currently under EMA review, based on OS data from KEYNOTE-042 [15].  
 
 
 
first global approval; 
FDA licensed for 
melanoma in September 
2014  
FDA: licensed first-line 
for metastatic NSCLC 
October 2016 
 
FDA: licensed first-line 
monotherapy for PD-L1-
expressing 
advanced/metastatic 
NSCLC in April 2019 
EMA approvals:  
first-line for high PD-L1 
metastatic NSCLC,  
in combination with 
chemotherapy for 
metastatic NSCLC; 
second-line  
 
application: extend first-
line indication to NSCLC 
with PD-L1 (TPS 1) 
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5 Burden of disease 
A0002: What is NSCLC? 
NSCLC is the most common epithelial lung cancer and accounts for approxi-
mately 80–85% of all lung cancers. Adenocarcinoma, the most frequent histo-
logical type, has a survival rate of approximately 4–6% at five years [16]. Ap-
proximately 7–35% of NSCLC patients have driver gene alterations in EGFR, 
ALK or ROS1, while 1–3% have BRAF mutations. The median survival for pa-
tients with metastatic disease without EGFR mutations or ALK rearrangements 
is approximately one year [17]. NSCLC tumours express the immune checkpoint 
PD-L1 that negatively regulates T-cell proliferation and induces cell death in tu-
mour-specific T-cells. Among patients with treatment-naïve, advanced NSCLC, 
30% express PD-L1 in a high percentage of tumour cells (TPS ≥50%), while 30–
50% of patients demonstrate a lower level of PD-L1 expression (TPS 1–49%) 
[11, 18]. 
 
A0004: What is the natural course of NSCLC? 
Lung cancer typically arises when epithelial cells lining the bronchial tubes 
undergo aberrant cell growth. To facilitate treatment, lung cancer is staged 
from I through IV based on tumour size, and presence or absence of lymph 
node involvement and metastases (TNM). Stage I lung cancer is <3 cm and 
localized to one lobe; stage II has spread to other parts of the lung or lymph 
nodes; stage III may be large or spread to lymph nodes between the lungs; and 
stage IV has metastasized to the adjacent bones, lung, brain, liver or any other 
organ [15, 19]. 
 
A0006: What are the consequences of NSCLC for the society? 
Lung cancer is the second most commonly diagnosed cancer. While the imple-
mentation of smoking cessation programs and multidisciplinary treatments 
have reduced the incidence and mortality, 52–58% of lung cancer patients 
present with advanced-stage disease when curative treatment is no longer 
feasible. PD-L1 is a poor prognostic factor in NSCLC [20], leading to a high rate 
of relapse and early formation of micro-metastases [21]. 
 
A0023: How many people belong to the target population? 
Lung cancer is the leading cause of cancer-related death in men and the sec-
ond in women worldwide. The age standardized incidence rate for the Euro-
pean Standard Population was 57.9 per 100,000 persons per year in 2015. In 
Austria, 2,868 men and 2,009 women were newly diagnosed with lung cancer 
in 2016; and 3,949 people died due to lung cancer [22]. It was the second most 
common cancer in men and women (12% of all cancers). Approximately 6.2% 
of people will be diagnosed with lung cancer during their lifetime and approx-
imately one-third of newly diagnosed patients have distant metastases. As-
suming this, about 1,625 patients in Austria (2016) had metastatic NSCLC at 
the time of diagnosis. Over the past decade, both the age-standardized inci-
dence and the death rates were rising by 30% for women, while those of men 
fell by 13% and 17%, respectively. The average age at diagnosis is approxi-
mately 70 years [16]. 
NSCLC accounts for 80–
85% of all lung cancers 
PD-L1 expression: 
TPS ≥50% in 30%;  
TPS 1–49% in 30–50% of 
patients 
staged I-IV by 
invasiveness 
 
metastasizes to bone, 
liver, brain, lymph nodes 
52–58% present with 
advanced cancer; 
relapse and metastasize 
early 
4,877 Austrians were 
diagnosed with NSCLC 
in 2016 
 
about 1,625 patients 
diagnosed with 
metastatic NSCLC in 
Austria (2016) 
 
 
 
average age at diagnosis 
70 years 
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A0005: What are the symptoms and the burden of disease or health condition? 
Many lung cancers are not symptomatic until they have spread. Symptoms of 
NSCLC include incessant cough, bloody sputum, chest pain, wheezing or 
hoarseness, weight loss or loss of appetite, shortness of breath, fatigue, and 
recurrent bronchitis or pneumonia. Lung cancer may metastasize to bone, 
brain, liver or lymph nodes causing pain, headaches, improper balance, sei-
zures, jaundice or lumps near the body’s surface [23]. 
 
A0003: What are the known risk factors for NSCLC? 
Overall, the risk of lung cancer increases with age, tobacco use, radiation ex-
posure, air pollution, and occupational exposure to asbestos, arsenic, chro-
mium beryllium, nickel, second-hand smoking and other agents. The risk of 
developing lung cancer is typically tenfold higher in smokers compared to life-
time non-smokers. Smoking cessation decreases precancerous lesions and re-
duces the risk of developing lung cancer [19, 23]. 
 
A0024: How is NSCLC currently diagnosed according to published guidelines 
and in practice? 
While some lung cancers may be found through screening, most are identified 
when they become symptomatic. Following a clinical history and physical 
exam, a chest x-ray may be done to identify any abnormal areas in the lungs. 
A computed tomography (CT) scan may show the size, shape and location of 
any lung tumours or enlarged lymph nodes, and guide a needle biopsy if a sus-
pected area is identified. Lung cancer is diagnosed by examining cells derived 
through biopsy, cytology or sputum sampling for the presence of cancer cells. 
IHC and molecular tests may be conducted to identify specific changes in the 
gene expression of cancer cells to target first-line treatment for NSCLC pa-
tients with genetic aberrations in EGFR, ALK or ROS1 genes [24, 25]. While a 
variety of assays are available to evaluate PD-L1 expression on tumour cells, 
PD-L1 IHC 22C3 pharmDx is the only companion diagnostic that is approved 
by the FDA and CE marked for European use in guiding pembrolizumab ther-
apy [7]. 
 
 
6 Current treatment 
A0025: How is NSCLC currently managed according to published guidelines 
and in practice? 
Depending on the tumour stage, histology, and the patients’ overall health, 
surgery, radiation therapy and/or platinum-based chemotherapy may be 
used alone or in combination to treat NSCLC. Treatment per NSCLC stages in-
volves the following options [19].  
 Stage I and II NSCLC patients typically undergo surgery to remove the 
cancer. Stage II patients and a subset of patients with stage Ib tumours 
may benefit from postoperative adjuvant chemotherapy.  
NSCLC symptoms 
include: cough, chest 
pain, weight loss, 
shortness of breath 
main risk factor: 
smoking 
diagnosis: x-ray, CT and 
biopsy 
 
 
 
 
 
 
 
 
PD-L1 status: IHC assay 
treatment by NSCLC 
stage: surgery, radiation 
therapy, chemotherapy 
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 Patients with stage I or II cancers that are not surgical candidates, due 
to co-morbidities or limited lung function, may undergo local radiation 
therapy.  
 Stage III NSCLC patients are highly heterogeneous and may undergo a 
combination of treatment modalities including chemotherapy and ra-
diation and/or surgery depending on the extent and localization of dis-
ease.  
 Patients with stage IV disease are treated with systemic therapy or a 
symptom-based palliative approach.  
 
In appropriately selected patients, chemotherapy, molecularly targeted ther-
apy, and/or immunotherapy may be used to treat advanced or metastatic 
NSCLC [25-28]. 
 While the optimal chemotherapy regimen for use with concurrent ra-
diotherapy is not known, cisplatin plus etoposide, carboplatin, or vi-
norelbine and paclitaxel are commonly used. Chemotherapy upregu-
lates PD-L1 expression on tumour cells, resulting in additive and syn-
ergistic antitumor activity. Combination pemetrexed and cisplatin is 
recommended for non-squamous NSCLC patients. 
 The standard dose fractionation regimen of radiotherapy with chemo-
therapy for stage III NSCLC is 60 Gy in 30 daily fractions. Intensity mod-
ulated radiation therapy is preferred over 3D radiotherapy due to the 
reduced risk for pneumonitis.  
 Patients with ALK translocations benefit from crizotinib, ceritinib, 
alectinib, lorlatinib or brigatinib therapy. First-line therapy for ROS1-
translocated NSCLC is crizotinib, cabozantinib, or ceritinib. Loratinib 
may be used following progression on ceritinib, brigatinib or alectinib. 
First-line therapy for stage IV patients with BRAF V600E is combina-
tion dabrafenib plus trametinib. Advanced neurotrophic receptor tyro-
sine kinase (NTRK)-positive NSCLC may benefit from second-line 
larotrectinib or entrectinib. 
 Patients with EGFR mutations may benefit from TKIs such as first gen-
eration erlotinib or gefitinib, or second-generation afatinib or 
dacomitinib. Third generation TKI osimertinib also targets the EG-
FRT790M mutation associated with acquired resistance to EGFR-TKIs.  
 Pembrolizumab, nivolumab, atezolizumab, and durvalumab block PD-
L1 on T-lymphocytes and are used as second-line therapies for ad-
vanced NSCLC. Pembrolizumab is recommended as first-line mono-
therapy for metastatic NSCLC exhibiting high PD-L1 expression with-
out EGFR or ALK aberrations; those with rapid disease progression 
may benefit from concurrent chemotherapy. Non-squamous and squa-
mous NSCLC patients with low PD-L1 expression may benefit from 
pembrolizumab in combination with pemetrexed and carboplatin or 
cisplatin, respectively. Alternatively nonsquamous NSCLC patients 
may receive combination platinum-based chemotherapy, bevaci-
zumab, and atezolizumab. An application to extend the first-line indi-
cation of pembrolizumab in NSCLC patients with PD-L1 (TPS 1) is un-
der EMA review. While combined nivolumab and ipilimumab provided 
NSCLC patients with PD-L1 expression >1% in the CheckMate 227 trial 
improved PFS compared with chemotherapy, further data is awaited 
to determine the role of nivolumab and ipilimumab in the first-line 
management of advanced NSCLC. 
advanced or metastatic 
NSCLC 
 
 
 
 
 
 
 
 
 
 
 
 
targeted therapies 
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7 Evidence 
A literature search was conducted on 17 July 2019 in five databases: the 
Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. Search 
terms were “pembrolizumab”, “Keytruda”, “L01XC18”, “non small cell lung 
cancer”, “NSCLC”, “lung cancer”, “metastatic”, “locally advanced”, “Pro-
grammed cell death 1 ligand 1” and “PD-L1”. The manufacturer was also con-
tacted and submitted three oral presentations [29-31], two conference ab-
stracts [32, 33], a clinical trial [6] and a pooled analysis [34], of which one was 
previously identified by systematic literature search [6]. A manual search 
identified two statistical reports [16, 22], six FDA approval documents [4, 7, 
10, 35-37], three EMA marketing authorization notifications [3, 5, 15], eight 
clinical guidance documents [19-21, 23, 24, 26-28], three clinical trial articles  
[8, 11, 12] and a cost document [38]. Ongoing trials information was found on 
www.clinicaltrials.gov and www.clinicaltrialsregister.eu. 
Overall, 144 references were identified. Included in this reported are:  
 KEYNOTE-042, phase III [6, 39] 
 KEYNOTE-024, phase III [11] 
To assess the risk of bias at the study level, the assessment of the methodo-
logical quality of the evidence was conducted based on the EUnetHTA internal 
validity for randomised controlled trials (RCTs) [40]. Evidence was assessed 
based on the adequate generation of the randomisation sequence, allocation 
concealment, blinding of patient and treating physician, selective outcome re-
porting and other aspects that may increase the risk of bias. Study quality de-
tails are reported in Table 5 of the Appendix. 
The external validity of the included trial was assessed using the EUnetHTA 
guideline on applicability of evidence in the context of a relative effectiveness 
assessment of pharmaceuticals, considering the following elements: popula-
tion, intervention, comparator, outcomes and setting [41]. 
To evaluate the magnitude of “meaningful clinical benefit” that can be ex-
pected from a new anti-cancer treatment, the Magnitude of Clinical Benefit 
Scale developed by the European Society for Medical Oncology (ESMO-MCBS) 
was used [42]. Additionally, an adapted version (due to perceived limitations) 
of the ESMO-MCBS was applied [43]. Details of the magnitude of the clinically 
meaningful benefit scale are reported in Table 3. 
systematic literature 
search in 5 databases:  
115 hits 
 
 
manual search: 29 
additional references 
overall: 144 references 
included: 2 studies 
study level risk of bias 
assessed based on 
EUnetHTA internal 
validity for RCTs 
magnitude of 
meaningful clinical 
benefit assessed based 
on ESMO-MCBS 
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7.1 Quality assurance  
This report has been reviewed by an internal reviewer and an external re-
viewer. The latter was asked for the assessment of the following quality crite-
ria: 
 How do you rate the overall quality of the report? 
 Are the therapy options in the current treatment section used in clin-
ical practice and are the presented standard therapies correct? 
 Is the data regarding prevalence, incidence, and amount of eligible 
patients correct? 
 Are the investigated studies correctly analysed and presented (data 
extraction was double-checked by a second scientist)? 
 Was the existing evidence from the present studies correctly inter-
preted? 
 Does the current evidence support the final conclusion? 
 Were all important points mentioned in the report? 
The LBI-HTA considers the external assessment by scientific experts from dif-
ferent disciplines a method of quality assurance of scientific work. The final 
version and the policy recommendations are under full responsibility of the 
LBI-HTA. 
 
7.2 Clinical efficacy and safety –  
phase III studies 
KEYNOTE-042 (NCT02220894) is an ongoing, multicentre, randomised, 
open-label, interventional phase III study involving 1,274 previously un-
treated patients with PD-L1-expressing advanced or metastatic NSCLC, with-
out EGFR or ALK mutations [6]. The study was designed to evaluate whether 
pembrolizumab prolongs OS compared to standard of care platinum-based 
chemotherapy. Efficacy analyses were based on all randomly assigned pa-
tients comprising the intent-to-treat (ITT) population. Safety analyses in-
volved all patients who received at least one dose of the study drug; 636 pa-
tients in the pembrolizumab group and 615 in the chemotherapy group. The 
study has an estimated completion date of March 2021; however, results of 
the second interim analysis, as reported by Mok et al 2019 [6], are discussed 
in this review. 
Eligible patients were 18 years or older, with untreated, pathologically con-
firmed, PD-L1-expressing locally advanced or metastatic NSCLC, without 
EGFR or ALK mutations. Patients were excluded if they had symptomatic cen-
tral nervous system (CNS) metastases, a history of non-infectious pneumon-
itis requiring glucocorticoids, active autoimmune disease, were receiving sys-
temic immunosuppressant therapy, or had a known active hepatitis B or C vi-
rus infection. Study participants were stratified by region of enrolment (Asia 
versus rest of world), Eastern Cooperative Oncology Group (ECOG) perfor-
mance status score (0 versus 1), histology (squamous versus non-squamous), 
and PD-L1 TPS (≥50% versus 1–49%).  
internal and 
external review  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
quality assurance 
method 
 
KEYNOTE-042: 
pembrolizumab versus 
chemotherapy as first-
line treatment for PD-
L1-expressing advanced 
or metastatic NSCLC 
ITT (n = 1,274): 
stratified by region, 
ECOG status, histology, 
and PD-L1 TPS 
Pembrolizumab as first-line therapy for PD-L1-expressing, locally advanced or metastatic NSCLC 
LBI-HTA | 2019 15 
Patients were randomised 1:1 to receive pembrolizumab (200 mg IV) every 
three weeks for up to 35 cycles, or investigator’s choice of carboplatin (area 
under the curve [AUC] 5–6 mg/mL/min, maximum dose 750–900 mg) with 
paclitaxel (200 mg/m2 IV) or pemetrexed (500 mg/m2 IV) every three weeks 
for up to six cycles. Participants with non-squamous histologies received op-
tional pemetrexed (500 mg/m2 IV) every three weeks. Patients were treated 
until progression or unacceptable toxicity. Cross-over from chemotherapy to 
pembrolizumab was not permitted. Pembrolizumab was withheld for drug-
related toxicities and severe or life-threatening AEs. Chemotherapy partici-
pants received vitamin B12 (1,000 mg) a week prior to their first dose of 
pemetrexed (and every three cycles thereafter), folic acid (350–1,000 mcg 
daily), and were pre-medicated with oral or injectable steroids. In the as-
treated population, the median number of doses administered was nine 
(range 1–36) in the pembrolizumab group and six (range 1–42) in the chem-
otherapy group.  
While the trial is estimated for completion in March 2021, the first interim 
analysis was conducted on August 30, 2017, six months after the final patient 
was enrolled. The second interim analysis was conducted on February 26, 
2018, 38.3 months after the first patient was enrolled. At second interim anal-
ysis, median follow-up of 12.8 months (interquartile range [IQR] 6.0–20.0), 
14% (87/636) of pembrolizumab patients continued treatment and 5% 
(30/615) of chemotherapy patients were receiving pemetrexed maintenance 
therapy. At least one subsequent anticancer therapy was received by 38% 
(240/637) of patients in the pembrolizumab group and 44% (383/637) of 
patients in the chemotherapy group, including 19 (3%) and 126 (20%) who 
received subsequent immunotherapy, respectively. After excluding patients 
still taking pembrolizumab or those who completed or discontinued treat-
ment without later disease progression, 51% (240/474) of patients in the 
pembrolizumab group and 56% (282/504) of patients in the chemotherapy 
group received subsequent therapy. 
The primary endpoint was OS (time from randomisation to all-cause death). 
Secondary endpoints were PFS (time from randomisation to RECIST-defined 
disease progression or all cause death) and ORR (percentage of patients with 
a confirmed complete [CR] or partial response [PR]) as assessed by independ-
ent central radiologic review (BICR), and safety. Endpoints were evaluated up 
to 38 months after randomisation. Efficacy hypotheses were analysed sequen-
tially by PD-L1 TPS, in the order of 50% or greater, 20% or greater, then 1% 
or greater. Hypotheses were tested only if the superiority of pembrolizumab 
over chemotherapy was established for the preceding hypothesis. Explora-
tory endpoints were OS, PFS, and ORR in patients with PD-L1 TPS 1–49%. Tu-
mours were assessed according to RECIST version 1.1 at baseline, every nine 
weeks for 45 weeks, and every twelve weeks thereafter. Patients were con-
tacted every two months to assess survival. AEs were graded for severity ac-
cording to the National Cancer Institute Common Terminology Criteria 
(CTCAE) version 4.0.  
The ITT population (n = 1,274) had a median age of 63 years (range 57–69), 
70% were male, 30% were East Asian, 78% were current or former smokers, 
38% had squamous histology, 69% had an ECOG performance score of 1, 5% 
had brain metastases, and 47% had a PD-L1 TPS ≥50% at randomisation. De-
tailed patient characteristics including inclusion- and exclusion criteria can be 
found in Table 5 and study quality is described in Table 6 of the appendix, 
respectively. Clinical efficacy data are presented in Table 1 and AEs are listed 
in Table 2.  
200 mg pembrolizumab 
versus carboplatin + 
paclitaxel or pemetrexed 
 
median number of 
doses: 9 for 
pembrolizumab versus 6 
for chemotherapy 
continued treatment at 
12.8 months: 14% of 
pembrolizumab and 5% 
of chemotherapy 
patients  
 
subsequent therapy: 
51% of pembrolizumab 
and 56% of 
chemotherapy patients 
primary endpoint: OS 
 
secondary endpoints: 
PFS, ORR, and safety 
 
exploratory endpoints: 
OS, PFS, and ORR for 
PD-L1 TPS 1–49 
ITT: median age 63 
years, 30% East Asian, 
78% smokers, 38% 
squamous histology, 
69% ECOG score of 1, 
47% PD-L1 TPS ≥ 50  
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7.2.1 Clinical efficacy 
 
D0001: What is the expected beneficial effect of pembrolizumab on mortality? 
The primary endpoint of median OS for the PD-L1 TPS ≥50% population was 
20.0 months (95% confidence interval [CI] 15.4–24.9) in the pembrolizumab 
group and 12.2 months (95% CI 10.4–14.2) in the chemotherapy group. In the 
PD-L1 TPS ≥20% population, median OS was 17.7 months (95% CI 15.3–
22.1) for pembrolizumab recipients and 13.0 months (95% CI 11.6–15.3) for 
chemotherapy recipients. The median OS for the PD-L1 TPS ≥1% population 
was 16.7 months (95% CI 13.9–19.7) in the pembrolizumab group and 12.1 
months (95% CI 11.3–13.3) in the chemotherapy group. The estimated per-
centages of patients alive at 24 months in the pembrolizumab and chemother-
apy groups were 45% and 30%, respectively, in the PD-L1 TPS ≥50% popu-
lation; 41% and 30% in the PD-L1 TPS ≥20% population; and 39% and 28% 
in the PD-L1 TPS ≥1% population. The OS benefit of pembrolizumab over 
chemotherapy was demonstrated across all three PD-L1 TPS populations (PD-
L1 TPS ≥50%: n = 599, HR 0.69, 95% CI 0.56–0.85 p = 0.0003; PD-L1 TPS 
≥20%: n = 818, HR 0.77, 95% CI 0.64–0.92, p = 0.0020; PD-L1 TPS ≥1%: n = 
1,274, HR 0.81, 95% CI 0.71–0.93, p = 0.0018). In the exploratory subgroup 
analysis, median OS in the PD-L1 TPS 1–49% population was 13.4 months 
(95% CI 10.7–18.2) for pembrolizumab recipients and 12.1 months (95% CI 
11.0–14.0) in chemotherapy recipients (n = 675 PD-L1 TPS 1–49%, HR 0.92, 
95% CI 0.77–1.11 no statistically significant difference [NSSD]).  
 
D0006: How does pembrolizumab affect progression (or recurrence) of 
NSCLC? 
The secondary endpoint, BICR-assessed median PFS, was 7.1 months (95% CI 
5.9–9.0) in pembrolizumab recipients and 6.4 months (95% CI 6.1–6.9) in 
chemotherapy recipients in the PD-L1 TPS 50% or greater population; 6.2 
months (95% CI 5.1–7.8) and 6.6 months (95% CI 6.2–7.3) in the PD-L1 TPS 
20% or greater population; and 5.4 months (95% CI 4.3–6.2) and 6.5 months 
(95% CI 6.3–7.0) in the PD-L1 TPS 1% or greater population, respectively. As 
the difference in PFS between groups did not reach the pre-specified superi-
ority boundary in the PD-L1 TPS 50% or greater population (n = 599 TPS 
≥50%, HR 0.81, 95% CI 0.67–0.99 p = 0.0170), that for the PD-L1 TPS 20% 
or greater and 1% or greater populations was not tested.  
 
 
 
 
 
 
 
 
 
median OS 
pembrolizumab vs. 
chemotherapy:  
PD-L1 TPS ≥ 50: 20.0 
months vs. 12.2 months 
PD-L1 TPS ≥ 20: 17.7 
months vs. 13.9 months 
PD-L1 TPS ≥ 1: 16.7 
months vs. 12.1 months 
 
consistent OS benefit 
across PD-L1 TPS 
populations 
median PFS 
pembrolizumab vs. 
chemotherapy:  
PD-L1 TPS ≥ 50: 7.1 
months vs. 6.4 months 
PD-L1 TPS ≥ 20: 6.2 
months vs. 6.6 months 
PD-L1 TPS ≥ 1: 5.4 
months vs. 6.5 months 
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D0005: How does pembrolizumab affect symptoms and findings (severity, fre-
quency) of NSCLC? 
The secondary endpoint, BICR-assessed ORR was 39% (118/299; 95% CI 34–
45) in pembrolizumab recipients and 32% (96/300; 95% CI 27–38) in chem-
otherapy recipients in the PD-L1 TPS 50% or greater population; 33% 
(138/413; 95% CI 29–38) and 29% (117/405; 95% CI 25–34) in the PD-L1 
TPS 20% or greater population; and 27% (174/637; 95% CI 24–31) and 27% 
(169/637; 95% CI 23–30) in the PD-L1 TPS 1% or greater population, respec-
tively.  
The median duration of response (DOR) was 20.2 months in the pembroli-
zumab group in all PD-L1 TPS populations, and was 10.8 months, 8.3 months, 
and 8.3 months, respectively in the PD-L1 TPS 50% or greater, 20% or greater, 
and 1% or greater populations in the chemotherapy group.  
 
D0011: What is the effect of pembrolizumab on patients̕ body functions? 
Pembrolizumab may cause immune-mediated AEs including pneumonitis, co-
litis, hepatitis, endocrinopathies, and nephritis [4]. In the as-treated popula-
tion, immune-mediated AEs occurring exclusively in the pembrolizumab 
group include thyroiditis (2%), hepatitis (1%), hypophysitis (<1%), nephri-
tis (<1%), myocarditis (<1%), and pancreatitis (<1%). Hypothyroidism, 
pneumonitis, hyperthyroidism, skin reactions, colitis and adrenal insuffi-
ciency were more commonly reported in the pembrolizumab group than the 
chemotherapy group (77 [12%] versus 9 [1%], 53 [8%] versus 3 [<1%], 39 
[6%] versus 4 [<1%], 15 [2%] versus 2 [<1%], 7 [1%] versus 2 [<1%], and 4 
[<1%] versus 1 [<1%]). Pembrolizumab may cause foetal harm based on its 
mechanism of action. 
 
D0012: What is the effect of pembrolizumab on generic health-related quality 
of life? 
No evidence was reported regarding the effect of pembrolizumab on generic 
health-related QoL.  
 
D0013: What is the effect of pembrolizumab on disease-specific quality of life? 
No evidence was reported regarding the effect of pembrolizumab on disease-
specific QoL. 
 
 
 
 
 
 
 
 
 
median ORR and DOR 
pembrolizumab vs. 
chemotherapy:  
PD-L1 TPS ≥ 50: 39% vs. 
32%; 10.8 vs. 20.2 
months 
PD-L1 TPS ≥ 20: 33% vs. 
29%; 8.3 vs. 20.2 
months 
PD-L1 TPS ≥ 1: 27% vs. 
27%; 8.3 vs. 20.2 
months 
immune-mediated AEs: 
pneumonitis, colitis, 
hepatitis, nephritis, 
pancreatitis, thyroid 
disorders, and 
endocrinopathies 
 
foetal toxicity 
generic health-related 
QoL: no evidence 
 
disease-specific QoL: no 
evidence 
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Table 1: Efficacy results of KEYNOTE-042 second interim analysis [6, 39] 
Descriptive statistics 
and estimate variabil-
ity 
Treatment group Pembrolizumab Chemotherapy 
Number of subject 637 637 
Median OS, n; m (95% CI) 
  PD-L1 TPS ≥50 
  PD-L1 TPS ≥20 
  PD-L1 TPS ≥1 
  PD-L1 TPS 1–49% 
 
24 m OS, %1 
  PD-L1 TPS ≥50 
  PD-L1 TPS ≥20 
  PD-L1 TPS ≥1 
 
n = 299; 20.0 (15.4–24.9) 
n = 413; 17.7 (15.3–22.1) 
n = 637; 16.7 (13.9–19.7) 
n = 338; 13.4 (10.7–18.2) 
 
 
45 
41 
39 
 
n = 300; 12.2 (10.4–14.2) 
n = 405; 13.0 (11.6–15.3) 
n = 637; 12.1 (11.3–13.3) 
n = 337; 12.1 (11.0–14.0) 
 
 
30 
30 
28 
BICR-assessed median PFS, m (95% CI) 
  PD-L1 TPS ≥50 
  PD-L1 TPS ≥20 
  PD-L1 TPS ≥1 
 
7.1 (5.9–9.0) 
6.2 (5.1–7.8) 
5.4 (4.3–6.2) 
 
6.4 (6.1–6.9) 
6.6 (6.2–7.3) 
6.5 (6.3–7.0) 
BICR-assessed ORR, n/N; % (95% CI) 
  PD-L1 TPS ≥50 
  PD-L1 TPS ≥20 
  PD-L1 TPS ≥1 
 
118/299; 39 (34–45) 
138/413; 33 (29–38) 
174/637; 27 (24–31) 
 
96/300; 32 (27–38) 
117/405; 29 (25–34) 
169/637; 27(23–30) 
Median DOR, m 
  PD-L1 TPS ≥50 
  PD-L1 TPS ≥20 
  PD-L1 TPS ≥1 
 
20.2 
20.2 
20.2 
 
10.8 
8.3 
8.3 
Effect estimate per 
comparison 
 
Comparison groups Pembrolizumab versus chemotherapy 
OS (PD-L1 TPS 50) 
(primary endpoint) 
(subgroup analysis, n = 599) 
HR for death  0.69 
95% CI 0.56–0.85 
P-value 0.0003 
OS (PD-L1 TPS 20) 
(primary endpoint) 
(subgroup analysis, n = 818) 
HR for death  0.77 
95% CI 0.64–0.92 
P-value 0.0020 
OS (PD-L1 TPS 1) 
(primary endpoint) 
(subgroup analysis, n = 1,274) 
HR for death  0.81 
95% CI 0.71–0.93 
P-value 0.0018 
OS (PD-L1 TPS 1–49%, subgroup) 
(exploratory analysis) 
(subgroup analysis, n = 675) 
HR for death  0.92 
95% CI 0.77–1.11 
P-value NSS 
BICR-assessed PFS (PD-L1 TPS 50) 
(secondary endpoint) 
(subgroup analysis, n = 599) 
HR  0.81 
95% CI 0.67–0.99 
P-value 0.0170 
BICR-assessed PFS (PD-L1 TPS 20) 
(secondary endpoint) 
(subgroup analysis, n = 818) 
HR  0.94 
95% CI 0.80–1.11 
P-value NSS 
BICR-assessed PFS (PD-L1 TPS 1) 
(secondary endpoint) 
(subgroup analysis, n = 1,274) 
HR  1.07 
95% CI 0.94–1.21 
P-value NSS 
Abbreviations: BICR = blinded independent central review; CI = confidence interval; CR = complete response; DOR = duration of 
response; HR = hazard ratio; m = months; n = number; N = total number; NSS = not statistically significant; OR = odds ratio; ORR 
= objective response rate; OS = overall survival; PD-L1 = programmed death ligand 1; PFS = progression-free survival; PR = 
partial response; SD = stable disease; TPS = tumour proportion score 
 
 
                                                                        
1 Estimated percentages of patients alive at 24 months 
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7.2.2 Safety 
 
C0008: How safe is pembrolizumab in relation to the comparator(s)? 
In the safety population (n = 1,251), treatment-related AE of any grade oc-
curred in 63% of pembrolizumab patients and 90% of chemotherapy patients. 
AEs commonly reported in at least 5% of pembrolizumab and chemotherapy 
recipients respectively, included fatigue (8% versus 17%), increased alanine 
aminotransferase (ALT) (7% versus 9%), increased aspartate aminotransfer-
ase (6% versus 7%), decreased appetite (6% versus 18%), anaemia (6% ver-
sus 37%), diarrhoea (5% versus 7%), and nausea (5% versus 30%). The most 
commonly reported AE was hypothyroidism (11%) in pembrolizumab recip-
ients, and anaemia (37%) in chemotherapy recipients. Treatment-related AEs 
of grade ≥3 severity that occurred in 20 or more patients were pneumonitis 
in the pembrolizumab group, and anaemia, neutropenia, and decreased white 
blood cells, platelets and neutrophils in the chemotherapy group. Treatment-
related AEs led to death in 13 (2%) pembrolizumab patients and 14 (2%) 
chemotherapy patients.  
 
C0002: Are the harms related to dosage or frequency of applying 
pembrolizumab? 
Patients received a median of nine (range 1–36) doses of pembrolizumab or 
six (range 1–36) doses of chemotherapy. Treatment-related AEs of grade ≥3 
severity were observed in 18% and 41% of patients in the pembrolizumab- 
and chemotherapy groups, respectively. Approximately 57 (9%) of pembroli-
zumab patients and 58 (9%) of chemotherapy patients discontinued treat-
ment. Pneumonitis occurred in 8% of pembrolizumab patients; events of 
grade ≥3 severity accounted for 23 (3%). One person died due to pneumon-
itis, concurrent with multiple comorbid conditions and disease progression. 
Pembrolizumab may cause severe or life-threatening infusion-related reac-
tions, including hypersensitivity and anaphylaxis [4]. Infusion-related reac-
tions were reported in 2% and 4% of patients in the pembrolizumab and 
chemotherapy groups, respectively.  
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of pembrolizumab? 
Study participants had a median age of 63 years (range 57–69) with good per-
formance status (ECOG 0–1). Patients with a history of autoimmune disease, 
immunodeficiency, active infections or uncontrolled illnesses were excluded 
from study. Subgroup analysis by age demonstrated no statistically significant 
difference in OS between study groups in patients older than 65 years of age. 
The clinical specificity of elderly patients with comorbidities, co-medication, 
reduced functional reserve and immunosenescence may affect the efficacy 
and or toxicity of immune-checkpoint inhibitors [44, 45]. 
Immune-mediated AEs occurred in 28% of pembrolizumab patients and 7% 
of chemotherapy patients. Events of grade ≥3 severity that occurred in five or 
more pembrolizumab recipients were pneumonitis, severe skin reactions, and 
hepatitis. One patient in the pembrolizumab group died due to pneumonitis 
concurrent with comorbid conditions and disease progression. While patients 
common AEs: 
hypothyroidism, 
fatigue, increased ALT/ 
AST, decreased appetite, 
anaemia, nausea and 
diarrhoea  
 
common grade ≥3 AEs: 
pneumonitis, pruritus, 
rash and myalgia 
 
deaths due to AEs: 2% 
for both groups  
9% discontinued 
pembrolizumab due to 
AEs 
 
grade ≥ 3 AEs: 3% due 
to pneumonitis 
 
 
infusion reaction: 2% 
for pembrolizumab vs. 
4% for chemotherapy 
susceptibles: elderly, 
comorbid, reduced 
functional status, 
immune compromised 
immune-mediated AEs: 
28% of pembrolizumab 
patients vs. 7% of 
chemotherapy patients  
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with compromised immune systems or autoimmune disease were excluded 
from the study population, side effects of greater severity may be expected in 
this population.  
Based on its mechanism of action, pembrolizumab may cause foetal harm and 
adverse reactions in breastfed infants. Females are advised to use effective 
contraception and not to breast feed for four months after taking their final 
dose [4]. 
 
Table 2: Most frequent adverse events of KEYNOTE-042 [6, 39] 
 
Adverse Event (according  
to CTCAE version 4.0) 
 
Pembrolizumab  
(n = 636) 
Chemotherapy  
(n = 615) 
 Any Grade  
n (%) 
Grade 3, 4, or 5 
n (%) 
Any Grade  
n (%) 
Grade 3, 4, or 5 
n (%) 
Any Event 339 (63) 113 (18) 553 (90) 252 (41) 
Discontinued due to AE 57 (9) 48 (8) 58 (9) 43 (7) 
Event leading to death 13 (2) 13 (2) 14 (2) 14 (2) 
 Event occurring in ≥  5% of patients in either group 
  Hypothyroidism 69 (11) 1 (<1) 2 (<1) 0 (0) 
  Fatigue 50 (8) 3 (<1) 102 (17) 8 (1) 
  Pruritus 46 (7) 2 (<1) 15 (2) 0 (0) 
  Rash  46 (7) 3 (<1) 27 (4) 0 (0) 
  ALT increased 45 (7) 9 (1) 53 (9) 5 (<1) 
     Pneumonitis 43 (7) 20 (3) 0 (0) 0 (0) 
  AST increased 41 (6) 4 (<1) 42 (7) 2 (<1) 
  Decreased appetite  40 (6) 5 (<1) 109 (18) 9 (1) 
  Hyperthyroidism 37 (6) 1 (<1) 1 (<1) 0 (0) 
  Anaemia 35 (6) 4 (<1) 229 (37) 80 (13) 
  Diarrhoea 34 (5) 5 (<1) 46 (7) 1 (<1) 
  Nausea 31 (5) 0 (0) 184 (30) 7 (1) 
  Arthralgia 27 (4) 0 (0) 46 (7) 0 (0) 
  Asthenia 27 (4) 3 (<1) 60 (10) 10 (2) 
  Myalgia 20 (3) 1 (<1) 50 (8) 0 (0) 
  Vomiting 15 (2) 0 (0) 97 (16) 2 (<1) 
  Leukopenia 10 (2) 0 (0) 35 (6) 10 (2) 
  Constipation 8 (1) 0 (0) 68 (11) 0 (0) 
  Stomatitis 7 (1) 0 (0) 31 (5) 0 (0) 
  Neutropenia 5 (<1) 1 (<1) 88 (14) 46 (7) 
  PSN 3 (<1) 0 (0) 41 (7) 6 (1) 
  Thrombocytopenia 3 (<1) 1 (<1) 56 (9) 10 (2) 
  WBC count decreased 3 (<1) 0 (0) 71 (12) 32 (5) 
  Alopecia 2 (<1) 0 (0) 136 (22) 7 (1) 
  Neutrophil count decreased 2 (<1) 0 (0) 86 (14) 54 (9) 
  Platelet count decreased 2 (<1) 0 (0) 64 (10) 20 (3) 
  Neuropathy peripheral 1 (<1) 0 (0) 50 (8) 5 (<1) 
 
pembrolizumab may 
cause foetal harm 
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 Adverse events of interest in the as-treated population 
  Any event 177 (28%) 51 (8) 44 (7) 9 (1) 
  Hypothyroidism  77 (12) 1 (<1) 9 (1) 0 (0) 
  Pneumonitis 53 (8) 23 (3) 3 (<1) 1 (<1) 
  Hyperthyroidism 39 (6) 1 (<1) 4 (<1) 0 (0) 
  Severe skin reactions 15 (2) 11 (2) 2 (<1) 1 (<1) 
  Infusion reactions 10 (2) 1 (<1) 26 (4) 6 (1) 
    Thyroiditis 10 (2) 0 (0) 0 (0) 0 (0) 
  Hepatitis 9 (1) 7 (1) 0 (0) 0 (0) 
  Colitis 7 (1) 4 (<1) 2 (<1) 1 (<1) 
  Adrenal insufficiency 4 (<1) 2 (<1) 1 (<1) 0 (0) 
  Hypophysitis  3 (<1) 3 (<1)  0 (0) 0 (0) 
  Nephritis 3 (<1) 1 (<1) 0 (0) 0 (0) 
  Myocarditis 1 (<1) 1 (<1) 0 (0) 0 (0) 
  Pancreatitis 1 (<1) 0 (0) 0 (0) 0 (0) 
Abbreviations: AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CTCAE = 
Common Terminology Criteria for Adverse Events; PSN = peripheral sensory neuropathy 
 
 
7.3 Clinical effectiveness and safety –  
further studies 
KEYNOTE-024 (NCT02142738) is an ongoing multicentre, randomised, open-
label, phase III trial to evaluate the safety and efficacy of first-line pembroli-
zumab monotherapy versus platinum-based chemotherapy in 305 patients 
with PD-L1 expressing metastatic NSCLC, without EGFR or ALK mutations 
[11]. Patients were randomised 1:1 to pembrolizumab (200 mg IV) every 
three weeks for 35 cycles or investigator’s choice of platinum-based chemo-
therapy. Both cross-over to pembrolizumab following progression and treat-
ment beyond RECIST-defined progression were allowed based on investiga-
tor-assessed continued clinical benefit. The primary endpoint was BICR-as-
sessed PFS; secondary endpoints included OS, ORR and safety. Efficacy was 
assessed in the ITT population while safety was assessed in the as-treated 
population. Tumours were evaluated every nine weeks according to RECIST 
version 1.1. AEs were graded according to the CTCAE version 4.0.  
At a median follow-up of 11.2 months (range 6.3–19.7), median PFS was 10.3 
months (95% CI 6.7–not reached) for pembrolizumab versus 6.0 months 
(95% CI 4.2–6.2) for chemotherapy patients. The estimated OS rate at six 
months was 80.2% in the pembrolizumab group versus 72.4% in the chemo-
therapy group. Pembrolizumab statistically significantly improved PFS and 
OS compared to platinum-based chemotherapy as first-line treatment for PD-
L1-positive NSCLC (HR for progression or death, 0.50, 95% CI 0.37–0.68, p < 
0.001; HR for death, 0.60, 95% CI 0.41–0.89, p = 0.005, respectively). Com-
pared with chemotherapy, pembrolizumab increased the response rate 
(44.8% versus 27.8%, the median DOR (not reached [range 1.9+–14.5+] ver-
sus 6.3 months [range 2.1+–12.6+] and reduced treatment-related AEs 
(73.4% versus 90.0%, respectively).  
 
KENOTE-024: 
pembrolizumab versus 
chemotherapy as first-
line for PD-L1-positive 
NSCLC without EGFR or 
ALK aberrations  
BICR-assessed PFS and 
OS: 10.3 months and 
80.2% for 
pembrolizumab versus 
6.0 months and 72.4% 
for chemotherapy  
 
AEs: 73.4% for 
pembrolizumab versus 
90.0% for 
chemotherapy 
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8 Estimated costs 
A0021: What is the reimbursement status of the technology? 
In Austria, single-use vials of 50 mg pembrolizumab powder, for reconstitu-
tion (25 mg/mL) and transfer into an intravenous bag, are available at a cost 
of € 1,714.0 (ex-factory price) [38]. Administered as an intravenous infusion, 
a 200 mg dose of pembrolizumab would cost € 6,856.0, every three weeks for 
up to 35 cycles. A median of nine doses (range 1–36) of pembrolizumab would 
cost approximately € 61,704.0 (range € 6,856.0 - € 239,960). Pembrolizumab 
is indicated for metastatic NSCLC exhibiting PD-L1 expression without EGFR 
or ALK aberrations. Since up to 50% of treatment-naïve, advanced NSCLC ex-
press PD-L1 [11, 18] and approximately 1,625 patients in Austria (2016) had 
metastatic NSCLC at diagnosis [22], pembrolizumab would cost approximately 
€ 50,134,500.0 (9 dose treatment period) annually with additional costs for 
molecular testing and the treatment of AEs. 
 
 
9 Ongoing research 
Pembrolizumab was compared to chemotherapy as first-line treatment for 
advanced or metastatic NSCLC in two randomised phase III trials involving 
patients without targetable EGFR or ALK aberrations. KEYNOTE-024 enrolled 
patients with PD-L1 ≥50% [11], and KEYNOTE-042 enrolled patients with 
PD-L1 ≥1% [6]. Several studies are ongoing to investigate pembrolizumab as 
monotherapy or in combination with other targeted therapies or immuno-
therapies to treat various stages of NSCLC. In September 2019, searches of 
www.clinicaltrials.gov and www.clinicaltrialsregister.eu using the search 
terms “pembrolizumab” and “non-small cell lung cancer” yielded 162 other 
registered studies (two phase IV, 21 phase III, 135 phase I/II, and four one 
early phase I/other). Most studies were industry-sponsored or conducted in 
collaboration with industry. 
Selected recently completed and ongoing phase III or II studies evaluating 
pembrolizumab in patients with PD-L1-positive advanced NSCLC as first-line 
in combination with chemotherapy (KEYNOTE-189, KEYNOTE-407), with 
chemotherapy, bevacizumab, ipilimumab, erlotinib, or gefitinib (KEYNOTE-
021), with chemotherapy and canakinumab (CANOPY-1), with ipilimumab 
(KEYNOTE-598), with lenvatinib (LEAP-007), and with olaparib (KEYLYNK-
008): 
 NCT03950674 and NCT02578680: KEYNOTE-189 is a phase III, ran-
domised, double-blind trial to assess whether adding pembroli-
zumab to platinum-based chemotherapy increases OS and PFS in pa-
tients with untreated metastatic non-squamous NSCLC. Estimated 
study completion date is January 2020.  
 NCT02775435/ NCT03875092 and NCT03850444 (China exten-
sions): KEYNOTE-407 is a phase III, randomised, triple-blind, paral-
lel-group study to evaluate the safety and efficacy of carboplatin and 
paclitaxel or nano particle albumin-bound paclitaxel (nab-paclitaxel) 
€ 6,856.0 every 3 weeks 
 
9 doses of 
pembrolizumab:  
~ € 61,704.0 
162 registered studies 
7 phase II/III studies 
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with or without pembrolizumab as first-line treatment for metastatic 
squamous NSCLC. Estimated study completion date is February 
2021–March 2021. 
 NCT02039674: KEYNOTE-021 is a phase II, multi-cohort (cohort G), 
randomised, open-label trial to assess whether adding pembroli-
zumab to platinum-based chemotherapy, bevacizumab, ipilimumab, 
erlotinib or gefitinib increases ORR in treatment-naïve NSCLC pa-
tients. Estimated study completion date is October 2021.  
 NCT03631199: CANOPY-1 is a phase III, randomised, double-bind 
study to determine the safety and efficacy of pembrolizumab plus 
platinum-based chemotherapy with or without canakinumab in pre-
viously untreated patients with locally advanced or metastatic non-
squamous NSCLC. Estimated study completion date is October 2022.  
 NCT03302234: KEYNOTE-598 is a phase III, randomised, double-
blind trial to determine the efficacy of pembrolizumab in combina-
tion with either ipilimumab or placebo as first-line treatment in pa-
tients with metastatic NSCLC. Estimated study completion date is 
February 2024.  
 NCT03829332: LEAP-007 is a phase III, randomised, double-blind 
trial to assess whether combination pembrolizumab and lenvatinib 
increases PFS and OS in treatment-naïve patients with metastatic 
NSCLC compared to pembrolizumab monotherapy. Estimated study 
completion date is March 2024.  
 NCT03976362: KEYLYNK-008 is a phase III, randomised, triple-blind 
study to compare the efficacy of pembrolizumab plus maintenance 
olaparib versus pembrolizumab with maintenance olaparib placebo 
for increasing PFS and OS of in patients with squamous NSCLC. Esti-
mated study completion date is December 2024.  
 
 
10 Discussion 
Between 2014 and 2015, pembrolizumab was licensed, by the FDA and the 
EMA, as first-line monotherapy for PD-L1-positive metastatic NSCLC without 
EGFR or ALK aberrations (PD-L1 TPS ≥50%), and as second-line therapy for 
PD-L1-positive NSCLC with progression following platinum-based chemo-
therapy (PD-L1 TPS >1%). Approved concurrently, PD-L1 ICH 22C3 pharmDx 
is the only FDA and CE marked companion diagnostic assay for guiding pem-
brolizumab therapy [18]. Pembrolizumab was licensed as first-line monother-
apy for patients with any histology NSCLC and PD-L1≥50% based on PFS and 
OS data from the ongoing KEYNOTE-024 study [11, 46]. In April 2019, the FDA 
expanded first-line monotherapy indications to include stage III or IV NSCLC 
patients who are not candidates for surgery or chemoradiation, and whose 
tumours express PD-L1 TPS ≥1. An application to extend the first-line indica-
tion of pembrolizumab in NSCLC with PD-L1 TPS ≥1 is currently under EMA 
review based on OS data from KEYNOTE-042 [6, 15]. 
FDA and EMA:  
second-line: following 
platinum-based 
chemotherapy 
 
first-line: monotherapy 
for PD-L1 expressing 
NSCLC without EGFR or 
ALK aberrations (PD-L1 
TPS ≥ 50%) 
 
first-line extension for 
NSCLC (PD-L1 TPS 
≥ 1%): FDA approved, 
under EMA review  
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KEYNOTE-042, an ongoing, randomised, open-label, phase III trial compared 
the efficacy and safety of pembrolizumab (200 mg IV) versus platinum-based 
chemotherapy (carboplatin + paclitaxel or pemetrexed) as first-line mono-
therapy for 1,274 patients with PD-L1-expressing metastatic NSCLC. Com-
pared with chemotherapy, pembrolizumab increased OS by 7.8 months, 4.7 
months, and 4.6 months for patients with PD-L1 TPS ≥50%, ≥20%, and ≥1%, 
respectively. The OS benefit of pembrolizumab over chemotherapy was 
demonstrated across all three PD-L1 TPS populations; those with PD-L1 TPS 
≥50% derived the greatest benefit (n = 599 PD-L1 TPS ≥50%, HR 0.69, 95% 
CI 0.56–0.85 p = 0.0003; n = 818 PD-L1 TPS ≥20%, HR 0.77, 95% CI 0.64–
0.92, p < 0.0020; n = 1274 PD-L1 TPS ≥1%, HR 0.81, 95% CI 0.71–0.93, p < 
0.0018). However, an exploratory analysis did not find an OS benefit for those 
with PD-L1 TPS 1–49% (n = 675, 13.4 months versus 12.1 months; HR 0.92, 
95% CI 0.77–1.11 NSSD). Approximately 20% of chemotherapy recipients 
went on to receive subsequent immunotherapy. At second interim analysis, 
no significant differences in PFS or ORR were noted between groups in any 
PD-L1 TPS population. Pembrolizumab increased the duration of response by 
9.7 months compared to chemotherapy. 
Common AEs, reported in at least 5% of pembrolizumab recipients, include 
fatigue, increased ALT or AST, decreased appetite, anaemia, diarrhoea, and 
nausea. Immune-mediated AEs include hypothyroidism (12%), pneumonitis 
(8%), hyperthyroidism (6%), skin reactions (2%), hepatitis (1%), colitis 
(1%) and adrenal insufficiency (<1%) were also more commonly reported in 
pembrolizumab patients. Treatment-related AEs led to death in 13 (2%) pem-
brolizumab patients and 14 (2%) chemotherapy patients.  
The results of KEYNOTE-042 hold some limitations. No evidence was reported 
regarding the effect of pembrolizumab on generic or disease-specific QoL. 
However, QoL measures are needed to ensure patients achieve a clinically rel-
evant benefit over time despite manageable toxicity. While approximately 
12% of patients presented with brain metastases at baseline, no results were 
reported regarding the CNS activity of pembrolizumab. This is of substantial 
importance as NCLC patients frequently present with brain metastases and 
there is concern regarding the ability of pembrolizumab to penetrate the 
blood brain barrier [47]. Generalizability of the results may be limited in that 
while study participants had a median age of 63 years with a good perfor-
mance status, the average age at diagnosis is 70 years in clinical practice. The 
clinical activity in elderly patients with comorbidities, autoimmune disease, 
reduced functional reserve, and immunosenescence may affect the efficacy 
and/or toxicity of pembrolizumab. While a recent pooled analysis reported 
survival benefit with pembrolizumab compared with chemotherapy in those 
aged ≥75 years [31, 34], only a randomised clinical trial would define the ben-
efit in this population.  
Based on results of the KEYNOTE-042 study, in April 2019, the FDA expanded 
the originally approved indication of pembrolizumab monotherapy as a first-
line agent for all patients with PD-L1 TPS ≥1%, without EGFR or ALK aberra-
tions. The survival benefit of combination pembrolizumab with chemother-
apy over chemotherapy alone was demonstrated in NSCLC patients, including 
those with PD-L1 TPS 1–49%, in the KEYNOTE-189 and KEYNOTE-407 trials, 
respectively [13, 14]. These results suggest that patients with PD-L1 TPS1–
49% would benefit from combination pembrolizumab with chemotherapy as 
standard of care. However, without direct comparison trials, physicians and 
patients may need to discuss whether adding pembrolizumab to chemother-
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apy would provide greater individualized efficacy over pembrolizumab mon-
otherapy for those in other PD-L1 TPS populations considering the associated 
AEs.  
Several methodological limitations of KEYNOTE-042 compromise the internal 
and external validity of the phase III trial. Patients were randomised 1:1 pem-
brolizumab versus chemotherapy via an interactive voice/web-based re-
sponse system [39] that generated a random allocation sequence. However, 
allocation concealment was not maintained and may influence how partici-
pants were assigned to a given treatment group. Internal validity may be com-
promised in an open-label study where patients and treating physicians are 
aware of treatment allocation, and the investigator chooses the chemothera-
peutic comparator. While a BIRC assessed outcomes as a means of ensuring 
an unbiased estimate of treatment effect, OS is an objective outcome unlikely 
to bias the trial results. Selective reporting is unlikely, as the primary endpoint 
of OS and secondary endpoints of PFS, ORR and DOR were reported as speci-
fied in the protocol. Approximately 46.6% of patients enrolled had a TPS 
≥50%, which lends potential bias for the over-performing efficacy of pem-
brolizumab in the ITT population. Since, subgroup analyses can solely indicate 
potential benefits for patients, subsequent studies are necessary to clarify the 
efficacy and safety in a specific patient population [48, 49].. The risk of bias 
may be increased by industry involvement in funding the study, assisting with 
study design, data collection, analysis and interpretation, and writing of the 
report. 
Given the non-curative treatment setting of pembrolizumab and the statisti-
cally significant primary endpoint of median OS in the three TPS populations, 
we applied Form 2b of the ESMO-MCBS. The ESMO-MCBS was used in order 
to assess whether pembrolizumab satisfies the criteria for a “meaningful clin-
ical benefit” (score 4 or 5). Both the original v1.1 as well as the adapted ver-
sion of the MCBS were applied. Application of the original and the adapted 
versions of the ESMO-MCBS, to the KEYNOTE-042 study resulted in grades 4 
and 5 for the PD-L1 TPS ≥50% population, 2 and 3 for PD-L1 TPS ≥20%, and 
2 for both in those with PD-L1 TPS ≥1%, respectively. Therefore, a “meaning-
ful clinical benefit” of pembrolizumab could only be identified for patients 
with PD-L1 TPS ≥50%, according to the original scale and the adapted frame-
work. However, results for the two subgroups (PD-L1 TPS ≥20% and PD-L1 
TPS ≥50%) are limited due to the lack of information of adverse events for 
this specific patient population. 
The clinical efficacy and safety data from KEYNOTE-042 are consistent with 
previous studies that suggest pembrolizumab improves OS with manageable 
toxicity in untreated PD-L1-positive metastatic NSCLC patients lacking EGFR 
or ALK aberrations. Consistent with existing studies of PD-L1 inhibition, KEY-
NOTE-001 [8] and KEYNOTE-010 [9], the greatest relative survival benefit 
was achieved in patients with PD-L1 TPS ≥50%. However, these OS results 
should be interpreted with caution as nearly half of patients had PD-L1 ≥50%. 
No significant difference in OS was noted between groups for patients with 
PD-L1 TPS 1–49%. Heterogeneity in the OS data across PD-L1 TPS popula-
tions suggests that a substantial number of patients progress rapidly within 
six months of treatment without obtaining meaningful benefit from immuno-
therapy. In the phase III KEYNOTE-024 study, pembrolizumab monotherapy 
improved PFS and OS, and was associated with fewer AEs compared with plat-
inum-based chemotherapy in NSCLC patients with high PD-L1 expressing tu-
mours [11]. The OS observed in the PD-L1 TPS ≥50% population of KEY-
NOTE-042 was numerically lower than that reported in KEYNOTE-24 and was 
not accompanied by significant PFS benefits. While pembrolizumab increased 
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PFS by 4.3 months compared to chemotherapy in KEYNOTE-024, pembroli-
zumab conferred no statistically significant difference over chemotherapy in 
KEYNOTE-042. Discrepancy in PFS findings between studies may be due to 
differing regions of enrolment, smoking history and availability of subsequent 
therapy. Safety profiles were similar in that grade ≥3 treatment-related AEs 
were fewer with pembrolizumab than with chemotherapy. The incidence of 
most immune-mediated AEs was in keeping with those previously observed 
with pembrolizumab monotherapy [8, 9, 11]. 
Several studies are ongoing to investigate pembrolizumab as monotherapy or 
in combination with other targeted therapies or immunotherapies to treat 
various stages of NSCLC. Ongoing phase III trials KEYNOTE-189 and KEY-
NOTE-407 assess whether adding pembrolizumab to chemotherapy increases 
OS and PFS in non-squamous and squamous metastatic NSCLC, respectively. 
KEYNOTE-021 is a randomised, multi-cohort, open-label, phase II study to 
evaluate whether adding pembrolizumab to platinum-based chemotherapy, 
bevacizumab, ipilimumab, erlotinib, or gefitinib increases ORR in treatment-
naïve NSCLC patients. The safety and efficacy of pembrolizumab in combina-
tion with chemotherapy with or without canakinumab in patients with non-
squamous metastatic NSCLC is under evaluation in the phase III CANOPY-1 
trial. The randomised, double-blind trials, KEYNOTE-598 and LEAP-007, are 
evaluating the efficacy of pembrolizumab in combination with ipilimumab or 
lenvatinib, respectively versus pembrolizumab monotherapy for metastatic 
NSCLC. KEYLYNK-008, a phase III, randomised, triple-blind study is compar-
ing the efficacy of pembrolizumab plus maintenance olaparib versus pem-
brolizumab with maintenance olaparib placebo for increasing PFS and OS in 
squamous NSCLC.  
Administered as an intravenous infusion, the recommended dose of 200 mg 
of pembrolizumab costs € 6,856.0 every three weeks for up to 35 cycles. A 
median of nine doses (range 1–36) of pembrolizumab would cost approximately 
€ 61,704.0 (range € 6,856.0 - € 239,960). Pembrolizumab is indicated for met-
astatic NSCLC exhibiting PD-L1 expression without EGFR or ALK aberrations. 
Since up to 50% of treatment-naïve, advanced NSCLC express PD-L1 [11, 18] 
and approximately 1,625 patients in Austria (2016) had metastatic NSCLC at 
diagnosis [22], pembrolizumab would cost approximately € 50,134,500.0 (9 
dose treatment period) annually with additional costs for molecular testing 
and the treatment of AEs. 
Elevated PD-L1 expression is commonly used as a biomarker of therapeutic 
efficacy for pembrolizumab, nivolumab and atezolizumab. At least four mon-
oclonal antibodies (clones 22-C3, 28-8, SP142, and SP263) have been devel-
oped as companion diagnostics of different PD-1 or PD-L1 inhibitors. Re-
search comparing these four antibodies on different staining platforms 
demonstrates that three of four reagents are comparable in terms of sensitiv-
ity, specificity and reproducibility [50]. Standardization of PD-L1 testing is 
warranted due to the availability of various staining techniques, antibodies, 
and differing levels of positivity. There is currently no consensus on a thresh-
old defining PD-L1 positivity, multiple definitions that are used hamper com-
parison across studies. PD-L1 is not an ideal biomarker because of its dynamic 
status, it is inducible by interferon exposure, therefore tumours that do not 
express PD-L1 at baseline may become PD-L1-positive as a result of an inflam-
matory background [51]. In addition to PD-L1 expression, novel biomarkers 
are needed to identify patients most likely to benefit from pembrolizumab 
therapy. Total mutation burden, T-cell inflamed gene expression profile, PD-
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L2 expression, history of smoking and presence of specific tumour neoanti-
gens may be useful in predicting response to therapy [52]. Further research is 
needed regarding the mechanisms of primary and secondary resistance to 
identify the optimal treatment approach after first-line pembrolizumab and 
to evaluate the efficacy and safety of pembrolizumab in the real-world setting. 
Overall, the KEYNOTE-042 phase III, randomized, open-label study demon-
strates that first-line pembrolizumab monotherapy increases OS for patients 
with PD-L1-expressing metastatic NSCLC. Comprising 46.6% of the ITT popu-
lation, the greatest OS benefit of pembrolizumab over chemotherapy was ob-
served in patients with PD-L1 TPS ≥50%. No statistically significant differ-
ence in OS was noted between groups for those with PD-L1 TPS 1–49%; and 
no statistically significant differences in PFS or ORR were noted between 
groups in any PD-L1 TPS population. Data regarding QoL and CNS activity are 
needed to ensure patients derive a clinically relevant benefit over time despite 
manageable toxicity. Further biomarkers are needed to ensure the appropri-
ate patient selection and facilitate comparison with other immune checkpoint 
inhibitors. In the absence of direct comparison trials, physicians may need to 
discuss whether adding pembrolizumab to chemotherapy would provide 
greater individual efficacy than chemotherapy alone, especially for PD-L1 TPS 
1–49% patients. 
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Table 3: Benefit assessment based on original ESMO-MCBS and adapted benefit assessment based on adapted ESMO-MCBS [42, 43] 
ESMO-MCBS 
Active  
substance Indication 
PD-L1 
TPS 
n Int PE Form 
MG standard 
treatment 
months 
Efficacy Safety 
AJ FM MG 
months 
HR 
(95% CI) 
Score calculation PM Toxicity QoL 
Adapted 
ESMO-MCBS Pembrolizumab NSCLC ≥1%  1,274 NC OS 2a >12-<24 +4.6 
0.81 
0.71-0.93 
HR > 0.75 OR Gain <1.5 
months 1 
-23% grade 
3-5 AEs NA +1 2 
Original 
ESMO-MCBS Pembrolizumab NSCLC ≥1% 1,274 NC OS 2a >12-<24 +4.6 
0.81 
0.71-0.93 
HR >0.70–0.75 AND Gain 
≥1.5 months 2 - NA - 2 
Adapted 
ESMO-MCBS 
Pembrolizumab NSCLC ≥20% 818 NC OS 2a >12-<24 +4.7 0.77 
(0.64-0.92) 
HR > 0.75 OR Gain <1.5 
months 
1 -23% grade 
3-5 AEs* 
NA +1 2 
Original 
ESMO-MCBS Pembrolizumab NSCLC ≥20% 818 NC OS 2a >12-<24 +4.7 
0.77 
(0.64-0.92) 
HR ≤0.70 AND Gain ≥3-<5 
months 
3 - NA - 3 
Adapted 
ESMO-MCBS 
Pembrolizumab NSCLC ≥50% 599 NC OS 2a >12-<24 +7.8 
0.69  
(0.56-0.85) 
HR ≤0.70 AND Gain ≥5 
months 
4 -23% grade 
3-5 AEs* 
NA +1 5 
Original 
ESMO-MCBS Pembrolizumab NSCLC ≥50% 599 NC OS 2a >12-<24 +7.8 
0.69 
(0.56-0.85) 
HR ≤0.70 AND Gain ≥5 
months 
4 - NA - 4 
Abbreviations: AJ = Adjustments; CI = confidence interval; FM = final adjusted magnitude of clinical benefit grade; HR = hazard ratio; Int = treatment intention; m = months; MG = median gain; NA = not available; OS = overall 
survival; PE = primary endpoint; PM = preliminary magnitude of clinical benefit grade; QoL = quality of life; * Adverse events are based on the total population and not on the respective subgroup population. 
DISCLAIMER 
The scores achieved with the ESMO Magnitude of Clinical Benefit Scale are influenced by several factors: by the specific evaluation form used, by the confidence interval (CI) of the endpoint of 
interest, and by score adjustments due to safety issues. Ad form: Every individual form measures a different outcome. The meaning of a score generated by form 2a is not comparable to the exact 
same score resulting from the use of form 2c. To ensure comparability, we report the form that was used for the assessment. Ad CI: The use of the lower limit of the CI systematically favours drugs 
with a higher degree of uncertainty (broad CI). Hence, we decided to avoid this systematic bias and use the mean estimate of effect. Ad score adjustments: Cut-off values and outcomes that lead 
to an up- or downgrading seem to be arbitrary. In addition, they are independent of the primary outcome and, therefore, a reason for confounding. Hence, we report the adjustments separately. 
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Table 4: Administration and dosing of pembrolizumab or chemotherapy [4-6, 39] 
 Pembrolizumab Chemotherapy 
Administration 
mode 
Pembrolizumab IV over 30 minutes [4] 
Carboplatin AUC 5 or 6 IV over 30-60 minutes; 
pemetrexed IV over 10 minutes; paclitaxel IV over 3 
hours or local standard practice [39] 
Description of 
packaging 
50 mg white lyophilized powder in a sin-
gle-dose vial for reconstitution using 2.3 
mL of sterile water (resulting concentra-
tion 20 mg/mL); 100 mg/mL (25 
mg/mL) colourless solution in a single-
dose vial; withdraw required volume 
from vial and transfer into IV bag con-
taining 0.9% sodium chloride injection, 
USP or 5% dextrose injection, USP (final 
concentration 1mg/mL-10 mg/mL) [4] 
Subjects received open label vials or kits containing 1 
vial per kit box. The name of the product, strength or 
potency was on the label text [39]. Carboplatin is sup-
plied as 600 mg/60 mL aqueous solution in multidose 
vials. Paclitaxel is available in 100 mg (16.7 mL) and 
300 mg (50 mL) multidose vials [36]. Pemetrexed is 
available in 500 mg vials [35]. 
Total volume 
contained in 
packaging for 
sale 
50 mg pembrolizumab powder formu-
lated in 3.1 mg L-histidine, 0.4 mg poly-
sorbate 80 and 140 mg sucrose in a sin-
gle-dose vial; 100 mg pembrolizumab in 
4 mL of solution in a single-dose vial [4] 
Carboplatin 10 mg/mL (60 mL) + paclitaxel 6 mg/mL 
(16.7 mL) or pemetrexed (500 mg/vial)  
Dosing 
Pembrolizumab (200 mg IV) every 3 
weeks for up to 35 treatments [6]. Dis-
continue pembrolizumab in patients 
with life-threatening AEs, grade 3/4 or 
recurrent pneumonitis, grade 4 diar-
rhoea/colitis, grade 3/4 elevated liver en-
zymes, hypophysis, hypothyroidism, ne-
phritis, myocarditis or other immune-
mediate AEs; withhold for grade 2 pneu-
monitis, grade 2/3 diarrhoea/colitis, 
grade 2 elevated liver enzymes, hypoph-
ysis or nephritis, grade 1/2 myocarditis 
or other immune-mediated AEs [39].  
Investigator’s choice of carboplatin AUC 5 or 6 + 
paclitaxel (200 mg/m2) or pemetrexed (500 mg/m2) 
every 3 weeks for up to 6 cycles, followed by optional 
pemetrexed 500 mg/m2 for patients with non-squa-
mous histology. Participants receive one intramuscu-
lar injection of vitamin B12 (1000 mcg) during week 
preceding first pemetrexed dose and every 3 cycles 
thereafter; and folic acid (350-100 mcg daily). Pa-
tients receiving chemotherapy should be pre-medi-
cated with oral or injectable steroids according to the 
approval product label and/or standard practice [39].  
Median treat-
ment duration 
Until DP, unacceptable toxicity, investi-
gator decision, patient withdrawal or up 
to 35 cycles of pembrolizumab [6]. 
Until DP unacceptable toxicity, investigator decision, 
patient withdrawal or up to 6 cycles of chemotherapy 
[6]. 
Contraindica-
tions 
None [4] 
Carboplatin is contraindicated in patients with bone 
marrow depression or bleeding [37]. Paclitaxel is con-
traindicated in AIDS-related Kaposi’s sarcoma (neu-
trophils <100 cells/mm3) or patients with neutrophils  
<1500 cells/mm3 [36]. Pemetrexed is contraindicated 
in those with history of hypersensitivity [35]. 
Drug interac-
tions 
Avoid systemic corticosteroids or immu-
nosuppressant’s prior to starting pem-
brolizumab [5] 
Carboplatin potentiates toxicity of nephrotoxic com-
pounds [37]. Caution use of paclitaxel with inhibitors 
and inducers of CYP2C8; interacts with CYP3A4.[36]. 
Caution use of ibuprofen or NSAIDs with pemetrexed 
[35]. 
Abbreviations: AE = adverse event; AIDS = acquired immunodeficiency syndrome; DP = disease progression; IV = intrave-
nous; NSAID = non-steroidal anti-inflammatory drugs; USP = United States Pharmacopeia  
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Table 5: Characteristics of KEYNOTE-042 [6] 
Title: Pembrolizumab versus chemotherapy for previously untreated, PD-L1 expressing, locally advanced or metastatic NSCLC (KEY-
NOTE-042): a randomised, open-label, controlled, phase 3 trial [6, 39] 
Study identifier NCT02220894, 3475-042, EudraCT2014-001473-14, JAPIC-CTI152877, MK-3475-042, KEYNOTE-042 
Design International (32 countries), multicentre (213 sites), randomised, open-label, interventional phase III 
Duration of main phase: Estimated trial duration of 3.5 years (first subject entry until last 
subject’s last visit); subject participation for 2.5 years. 3428 pa-
tients were screened; 3019 had samples evaluable for PD-L1 ex-
pression of whom 1978 had TPS 1. December 2014 – March 2017, 
1275 patients were randomised 1:1 to receive pembrolizumab (n = 
638) or chemotherapy (n = 637). One patient was assigned pem-
brolizumab after death; therefore, ITT included 637 in each group.  
Data cut-off: February 26, 2018  
Median follow-up: median follow-up 12.8 m (range 6.0–20.4) 
Mean number of doses: 9 (range 1–36) for pembrolizumab and 6 
(range 1–42) for chemotherapy 
 
Duration of Run-in phase: Not applicable 
Duration of Extension phase: At data cut-off, as-treated population, 636 (14%) of pembroli-
zumab and 615 (5%) of chemotherapy patients were still receiv-
ing assigned treatment. In the ITT population, 240 (38%) of pem-
brolizumab and 282 (44%) of chemotherapy patients received 1 
subsequent therapy, including 19 (3%) and 126 (20%) that re-
ceived subsequent immunotherapy. After excluding patients still 
taking pembrolizumab or those who had completed or discontin-
ued treatment without later progression, 240 (15%) of 474 pem-
brolizumab and 282 (56%) of 504 chemotherapy patients re-
ceived subsequent treatment.  
Hypothesis 
Superiority 
The primary hypothesis is that pembrolizumab prolongs OS compared to standard of care platinum-based 
chemotherapy. 
Funding Merk Sharp & Dohme Corp. 
Treatments groups 
 
Pembrolizumab 
(n = 637 efficacy; n = 636 safety; n = 
87/636 ongoing  and 42 completed 35 cy-
cles at data cut-off February 26, 2018) 
Pembrolizumab (200 mg IV) every 3 weeks for up to 35 treat-
ments, or until progression or unacceptable toxicity.  
Chemotherapy 
(n = 637 efficacy; n = 615 safety; n = 
615/636 ongoing and 160 completed 6 cy-
cles at data cut-off February 26, 2018) 
Investigators choice of platinum chemotherapy: carboplatin 
(AUC 5–6 mg/mL/minute, maximum dose 750–900 mg) + 
paclitaxel (200 mg/m2 IV) or pemetrexed (500 mg/m2 IV) every 
3 weeks for up to 6 cycles. Participants with non-squamous his-
tologies may receive optional treatment with pemetrexed (500 
mg/m2 IV) every 3 weeks. Patients are treated until progression 
or unacceptable toxicity. Crossover from chemotherapy to pem-
brolizumab was not permitted.  
Endpoints and  
definitions 
 
Overall survival 
Primary endpoint 
 
OS Time from randomization until all-cause death in participants 
with TPS of ≥ 50%, ≥ 20%, and ≥ 1% (up to 38 months) 
Progression-free survival 
Secondary endpoint 
PFS 
Time from randomization until BICR-assessed PD or all-cause 
death (RECIST v1.1) in participants with TPS of ≥ 50%, ≥ 20%, 
and ≥ 1%, (up to 38 months) 
Objective response rate 
Secondary endpoint 
ORR 
 
Percentage of participants with BICR-assessed CR or PR (RECIST 
v1.1), in those with TPS of ≥ 50%, ≥ 20%, and ≥ 1% (up to 38 
months) 
Adverse events 
Secondary endpoint 
AEs AEs graded by CTCAE version 4.0 (up to 38 months) 
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Title: Pembrolizumab versus chemotherapy for previously untreated, PD-L1 expressing, locally advanced or metastatic NSCLC (KEY-
NOTE-042): a randomised, open-label, controlled, phase 3 trial [6, 39] 
Study identifier NCT02220894, 3475-042, EudraCT2014-001473-14, JAPIC-CTI152877, MK-3475-042, KEYNOTE-042 
Discontinued treatment due 
to adverse events 
Secondary endpoint 
— 
Number of patients who discontinued study treatment due to 
an AE (up to 38 months) 
Notes 
In the original protocol, the primary endpoint of was OS in patients with PD-
L1 TPS ≥50%; secondary endpoints were OS in patients with PD-L1 TPS ≥1% 
and PFS in patients with TPS ≥50% and ≥1%. Exploratory endpoints were OS 
and PFS in patients with TPS of 1–49% and OR among those with TPS ≥50%, 
1–49%, and ≥1%. After enrolment of 662 patients in the KEYNOTE-010 
study, a significant OS benefit was reported in patients with previously 
treated advanced NSCLC and a PD-L1 TPS of ≥1%. Consequently, the primary 
endpoints of this study were amended to include PFS and OR, respectively, 
in these populations. At screening, PD-L1 expression was assessed with PD-
L1 IHC 22C3 pharmDx assay (Agilent Technologies, Carpinteria, CA, USA). 
Database lock Last update posted March 15, 2019 
Results and Analysis  
Analysis description Primary Analysis 
ITT: efficacy analyses included all patients randomized. Safety analysis included all patients who received at 
least one dose of study drug. Two interim analyses (August 30, 2017, 6 months after final patient enrolment; 
Feb 26, 2018, 38.3 months after first patient enrolment) and a final analysis were specified in the final proto-
col.  
OS and PFS were calculated using the Kaplan-Meier method for censored data. Efficacy hypotheses were ana-
lysed sequentially by TPS (50%, 20%, and 1%).  Hypotheses were tested only if superiority was estab-
lished for the preceding hypothesis. Family-wise type 1 error was controlled at a one-sided  = 0.025. Ac-
counting for the 0.01576  spent at first interim analysis, superiority boundaries were adjusted for multiplic-
ity with the Hwang-Shih-DeCani  spending function, with  parameter set at -0.9023 and an information 
fraction of 1166 of 1353 (number of study days to second interim analysis and planned final analysis, respec-
tively from date first patient was randomised).  Stratified log-rank test assessed between-group differences in 
OS and PFS. Stratified Cox regression with Efron’s method of tie handling was used to estimate HR and asso-
ciated 95% CIs. The stratified Miettinen and Nurminen method was used to assess between-group differences 
in response rate. All randomisation stratification factors were applied to all stratified analyses.  
A sample size of 1240 patients gave power at the following levels (one-sided  = 0.025): 99% to detect an 
HR of 0.65 among patients with TPS 50% with 398 deaths in the population; 98% to detect piecewise HRs 
of 0.80 from 0 to 6 months of treatment and 0.64 after 6 months of treatment among patients with TPS 
20% with 557 deaths; and 91% to detect piecewise HRs of 0.92 for 0 to 6 months of treatment and 0.73 af-
ter 6 months of treatment among patients with TPS 1 with 900 deaths. Piecewise HRs account for possible 
non-proportional hazards in the treatment effect. 
Analysis population   
Inclusion 
 Adults (aged ≥ 18 years) with histologically or cytologically-confirmed PD-L1-ex-
pressing locally advanced or metastatic NSCLC without sensitizing EGFR or ALK 
mutations, or previous systemic therapy for advanced or metastatic disease 
 Life expectancy ≥ 3 months, adequate organ function with ECOG performance-
status 0–1, ≥ 1 measurable lesion according to RECIST v1.1, and PD-L1 TPS ≥ 1% 
 Males with female partners, and females of childbearing potential willing to use 
adequate contraception up to 180 days post chemotherapy 
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Title: Pembrolizumab versus chemotherapy for previously untreated, PD-L1 expressing, locally advanced or metastatic NSCLC (KEY-
NOTE-042): a randomised, open-label, controlled, phase 3 trial [6, 39] 
Study identifier NCT02220894, 3475-042, EudraCT2014-001473-14, JAPIC-CTI152877, MK-3475-042, KEYNOTE-042 
 
Exclusion 
 NSCLC curatively treatable with surgical resection and/or chemoradiation, squa-
mous histology having received adjuvant carboplatin in combination with 
paclitaxel, or lack of tumour sample for PD-L1 determination 
 Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 anti-CD137, or CTLA-4 an-
tibody, including ipilimumab or a drug targeting T-cell co-stimulation or check-
point pathways 
 Received a study drug, investigational agent, or device within 4 weeks, systemic 
chemotherapy, biological therapy or major surgery within 3 weeks, or live vac-
cine within 30 days prior to first dose of study drug 
 Received systemic steroid therapy or an immunosuppressant ≤ 3 days prior to the 
first dose of study drug, except for daily steroid replacement therapy  
 Expected to require antineoplastic therapy during study 
 History of HIV, hepatitis B or C, malignancy with recurrence within 5 years, sub-
stance abuse, non-infectious pneumonitis requiring glucocorticoids, untreated 
CNS metastases, autoimmune disease or infection requiring systemic treatment, 
or allogenic tissue/solid organ transplantation 
 Pregnant, breastfeeding, or expecting to conceive or father children within the 
study duration 
 
Characteristics 
 
Pembrolizumab 
(n = 637) 
Chemotherapy 
(n = 637) 
TPS ≥ 50% 
(n = 299) 
TPS ≥ 20% 
(n = 413) 
TPS ≥ 1% 
(n = 637) 
TPS ≥ 50% 
(n = 300) 
TPS ≥ 20% 
(n = 405) 
TPS ≥ 1% 
(n = 637) 
Median age  
  (range), years 
  <65, n (%) 
63.0 
(56.0-68.0) 
167 (56) 
63.0 
(56.0-69.0) 
228 (55) 
63.0 
(57.0-69.0) 
359 (56) 
64.0 
(57.0-69.0) 
161 (54) 
64.0 
(57.0-69.0) 
212 (52) 
63.0 
(57.0-69.0) 
348 (55) 
Male, n (%) 205 (69) 283 (69) 450 (71) 210 (70) 285 (70) 452 (71) 
Region 
  East Asia 
  Europe 
  Latin America 
  Other 
 
92 (31) 
71 (24) 
53 (18) 
83 (28) 
 
128 (31) 
96 (23) 
78 (19) 
111 (27) 
 
185 (29) 
149 (23) 
136 (21) 
167 (26) 
 
94 (31) 
66 (22) 
63 (21) 
77 (26) 
 
121 (30) 
95 (23) 
82 (20) 
107 (26) 
 
185 (29) 
137 (22) 
133 (21) 
182 (29) 
ECOG perfor-
mance-status, n 
(%) 
  0 
  1 
 
 
 
96 (32) 
203 (68) 
 
 
 
122 (30) 
291 (70) 
 
 
 
198 (31) 
439 (69) 
 
 
 
91 (30) 
209 (70) 
 
 
 
131 (32) 
274 (68) 
 
 
 
192 (30) 
445 (70) 
Smoking status 
  Current 
  Former 
  Never 
 
57 (19) 
178 (60) 
64 (21) 
 
75 (18) 
243 (59) 
95 (23) 
 
125 (20) 
370 (58) 
142 (22) 
 
59 (20) 
174 (58) 
67 (22) 
 
85 (21) 
230 (57) 
90 (22) 
 
146 (23) 
351 (55) 
140 (22) 
Histology 
  Squamous 
  Non-squamous 
 
107 (36) 
192 (64) 
 
148 (36) 
265 (64) 
 
243 (38) 
394 (62) 
 
114 (38) 
186 (62) 
 
156 (39) 
249 (61) 
 
249 (39) 
388 (61) 
Disease status 
  Locally advanced 
  Metastatic 
 
27 (9) 
272 (91) 
 
42 (10) 
371 (90) 
 
76 (12) 
561 (88) 
 
35 (12) 
265 (88) 
 
51 (13) 
354 (87) 
 
84 (13) 
553 (87) 
BM 19 (6) 23 (6) 35 (5) 15 (5) 22 (5) 35 (5) 
PD-L1 TPS 
  1–19% 
  20–49% 
  ≥ 50% 
 
0 (0) 
0 (0) 
299 (100) 
 
0 (0) 
114 (28) 
299 (72) 
 
224 (35) 
114 (18) 
299 (47) 
 
0 (0) 
0 (0) 
300 (100) 
 
0 (0) 
105 (26) 
300 (74) 
 
232 (36) 
105 (16) 
300 (47) 
Previous therapy  
for non-metastatic  
  Radiotherapy 
  Neoadjuvant 
therapy 
  Adjuvant therapy 
 
 
40 (13) 
 
1 (<1) 
8 (3) 
 
 
53 (13) 
 
2 (<1) 
13 (3) 
 
 
75 (12) 
 
3 (<1) 
18 (3) 
 
 
39 (13) 
 
5 (2) 
4 (1) 
 
 
51 (13) 
 
7 (2) 
8 (2) 
 
 
81 (13) 
 
7 (1) 
12 (2) 
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Title: Pembrolizumab versus chemotherapy for previously untreated, PD-L1 expressing, locally advanced or metastatic NSCLC (KEY-
NOTE-042): a randomised, open-label, controlled, phase 3 trial [6, 39] 
Study identifier NCT02220894, 3475-042, EudraCT2014-001473-14, JAPIC-CTI152877, MK-3475-042, KEYNOTE-042 
Applicability of evidence 
Population 
KEYNOTE-042 was conducted in patients with PD-L1-expressing metastatic NSCLC without EGFR or ALK mu-
tations. Generalizability of the results may be limited in that while study participants were a median age of 64 
years with good performance status, the average age at diagnosis is 70 years. The clinical specificity in elderly 
patients with comorbidities, reduced functional reserve, and immunosenescence may affect the efficacy and 
or toxicity of pembrolizumab. 
Intervention 
The dosage and administration of pembrolizumab used in KEYNOTE-042 is consistent with that recommended 
for the treatment of NSCLC [4]. Pembrolizumab was withheld for drug-related toxicities and severe or life-
threatening AEs. Cross-over from chemotherapy to pembrolizumab was not permitted. 
Comparators 
The comparator arm may be suboptimal as cross-over is desirable in settings where a drug has proven benefit 
in a subsequent line of therapy and attempts are being made to advance it to an earlier line. Without direct 
comparison trials, physicians and patients may need to discuss whether adding pembrolizumab to chemother-
apy would provide greater individualised efficacy than pembrolizumab monotherapy.  
Outcomes 
No evidence was reported regarding the effect of pembrolizumab on generic or disease-specific QoL of CNS 
activity. QoL measures are needed to ensure patients achieve a clinically relevant benefit over time despite 
favourable tolerability, especially as other immunotherapies are not considered for comparison. NSCLC pa-
tients frequently present with brain metastases; there is concern regarding the ability of pembrolizumab to 
penetrate the blood brain barrier. 
Setting KEYNOTE-042 was a multinational, multicentre study where approximately 63% of patients were East Asian, 
48% were European, 43% were Latin American, and 57% were from other regions. 
Abbreviations: AE = adverse events; ALK = anaplastic lymphoma kinase; AUC = area under the curve; BICR = blinded independent central 
review; BM = brain metastases; CI = confidence interval; CNS = central nervous system; CR = complete response; CTCAE = Common 
Terminology Criteria for Adverse Events; CTLA-4 = anti-cytotoxic T-lymphocyte-associated antigen-4; ECOG = Eastern Cooperative Oncology 
Group; HIV = Human Immunodeficiency Virus; HR = hazard ratio; NSCLC = non-small cell lung cancer; ORR = objective response rate; OS = 
overall survival; PD = progressive disease; PD-1 = programmed cell death protein 1; PD-L1 = programmed death ligand 1; PD-L2 = programmed 
death ligand 2; PFS = progression-free survival; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumours; TPS = tumour 
proportion score 
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Table 6: Risk of bias assessment on study level is based on EUnetHTA (Internal validity of randomised controlled trials) [6, 40] 
Criteria for judging risk of bias  Risk of bias 
Adequate generation of randomisation sequence: randomisation schedule generated by a computerised 
randomised list generator held centrally; randomised 1:1 to pembrolizumab or chemotherapy using the 
IVRS/IWRS system. Randomisation was stratified by region of enrolment (Asia versus rest of world), ECOG 
performance status score (0 versus 1), histology (squamous versus non-squamous), PD-L1 TPS (≥ 50% ver-
sus   1–49%) and treatment was allocated in blocks of four in each stratum.  
yes 
Adequate allocation concealment:  no 
Blinding: 
Patient: due to differences in infusion durations, administration schedules, 
and premedication requirements, patients were not masked. no 
Treating physician: due to differences in infusion durations, administration 
schedules, and premedication requirements, investigators, members of the 
external data monitoring committee, and select representatives of the 
sponsor were not masked. 
no 
Outcome assessor: central radiological reviewers (BICR) were unaware of 
treatment assignment. yes 
Selective outcome reporting unlikely: primary outcomes include OS, PFS, ORR, AEs and discontinuation due 
to AEs, as per clinical trial report. Response and DP were assessed by BICR according to RECIST v1.1.  yes 
No other aspects which increase the risk of bias: industry funded the study, assisted with study design, data 
collection, analysis, interpretation and writing of the report.  no 
Risk of bias – study level high 
Abbreviations: BICR = blinded independent central review; DP = disease progression; ECOG = Eastern Cooperative Oncology Group; IVRS/IWRS 
– interactive web response system/interactive web response system; PD-L1 = programmed death ligand 1; TPS = tumour proportion score 
 
 
